Presentation is loading. Please wait.

Presentation is loading. Please wait.

Confirmation of synergy and cytotoxicity of genotype-selective drug pairs. Confirmation of synergy and cytotoxicity of genotype-selective drug pairs. A,

Published by Modified over 5 years ago

Similar presentations

Presentation on theme: "Confirmation of synergy and cytotoxicity of genotype-selective drug pairs. Confirmation of synergy and cytotoxicity of genotype-selective drug pairs. A,"— Presentation transcript:

1 Confirmation of synergy and cytotoxicity of genotype-selective drug pairs.
Confirmation of synergy and cytotoxicity of genotype-selective drug pairs. A, formal assessment of synergy of lapatinib or bosutinib with MK-2206, and simvastatin with flavopiridol or 17-DMAG on representative BRAF mutant and RAS mutant melanomas, by Chou–Talalay isobologram analysis. Data are normalized, with connecting line at X and Y = 1 corresponding to the line of additivity. Datapoints falling below line are synergistic, along or near the line are additive, and above the line are antagonistic (see key). Data represent averages for 3 separate experiments. Combination indices and growth inhibition values can be found in Supplementary Table S9. B, flow cytometry of Annexin-V and propidium iodide viability markers after lapatinib (2.5 μmol/L) and MK-2206 (5.0 μmol/L) treatment alone or in combination, or simvastatin (2.5 μmol/L) and flavopiridol (0.1 μmol/L) alone or in combination with representative lines YUMAC (BRAF mutant) or YUGASP (NRAS mutant). Numbers in the lower right quadrant correspond to early apoptotic cells, whereas numbers in the top right and left quadrants correspond to late apoptotic and necrotic cells, respectively. Flow cytometry for vehicle-only controls and other combinations are shown in Supplementary Fig. S3F. C, percent viability for combinations tested by flow cytometry, as in B. N = 3 for all experiments. Error bars, mean ± SD. P values calculated by Student t test; *, P < D, evaluation of drug-class effects. Representative concentration–response curves of single agents or dual-agent combinations showing enhanced growth inhibition in mutant BRAF cells, using the EGFR inhibitor gefitinib with MK-2206 (top row) or atorvastatin with flavopiridol in mutant RAS cells (bottom row) in relation to the predicted Bliss independence model. See also Supplementary Fig. S4. For statin combinations with flavopiridol, top and bottom x-axes represent concentrations used for each drug with those same concentrations used in combinations. Same-concentration combinations were used for gefitinib and MK-2206. Matthew A. Held et al. Cancer Discovery 2013;3:52-67 ©2013 by American Association for Cancer Research

Download ppt "Confirmation of synergy and cytotoxicity of genotype-selective drug pairs. Confirmation of synergy and cytotoxicity of genotype-selective drug pairs. A,"

Similar presentations

Supplementary Figure 1. The effect of 17-DMAG on the growth of lung cancer cells with Met amplification Tumor cells were continuously treated with increasing.

Supplementary Figure 1. The effect of 17-DMAG on the growth of lung cancer cells with Met amplification Tumor cells were continuously treated with increasing.
Supplementary Table S1. List of chemical inhibitors utilized in the current study. Supplementary Information.

Supplementary Table S1. List of chemical inhibitors utilized in the current study. Supplementary Information.
* Supplementary Figure 1: Treatment of siramesine with various chemotherapeutic drugs in MDA MB 231 cells. MDA MB 231 cells were treated with 10μM siramesine.

* Supplementary Figure 1: Treatment of siramesine with various chemotherapeutic drugs in MDA MB 231 cells. MDA MB 231 cells were treated with 10μM siramesine.
Drug concentration (μM)

Drug concentration (μM)
DNA content flow cytometric histograms of propidium iodide–stained A549 cells. DNA content flow cytometric histograms of propidium iodide–stained A549.

DNA content flow cytometric histograms of propidium iodide–stained A549 cells. DNA content flow cytometric histograms of propidium iodide–stained A549.
WEE1 inhibition forces S-phase–arrested cancer cells into mitosis.

WEE1 inhibition forces S-phase–arrested cancer cells into mitosis.
Figure 1. Artemisinin derivatives inhibited EOC growth and arrested the cell cycle at the G2/M phase (A) SKOV3 and primary epithelial ovarian cancer (EOC)

Figure 1. Artemisinin derivatives inhibited EOC growth and arrested the cell cycle at the G2/M phase (A) SKOV3 and primary epithelial ovarian cancer (EOC)
Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.

Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.
Synergistic action of dual IGF1/R and MEK inhibition sensitizes childhood acute lymphoblastic leukemia (ALL) cells to cytotoxic agents and involves downregulation.

Synergistic action of dual IGF1/R and MEK inhibition sensitizes childhood acute lymphoblastic leukemia (ALL) cells to cytotoxic agents and involves downregulation.
(a) (b) SUPPLEMENTARY FIGURE 1:

(a) (b) SUPPLEMENTARY FIGURE 1:
Effects of Betulinic Acid Alone and in Combination with Irradiation in Human Melanoma Cells  Edgar Selzer, Emilio Pimentel, Volker Wacheck, Werner Schlegel,

Effects of Betulinic Acid Alone and in Combination with Irradiation in Human Melanoma Cells  Edgar Selzer, Emilio Pimentel, Volker Wacheck, Werner Schlegel,
Volume 117, Issue 4, Pages (October 1999)

Volume 117, Issue 4, Pages (October 1999)
Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: Activation of the mitochondria-dependent death-signaling.

Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: Activation of the mitochondria-dependent death-signaling.
Fig. 4. Functional annotation of VUS in EGFR.

Fig. 4. Functional annotation of VUS in EGFR.
Fig. 2. Mutant KRAS mediates resistance to PARPi and sensitivity to PARPi and MEKi Mutant KRAS mediates resistance to PARPi and sensitivity to PARPi and.

Fig. 2. Mutant KRAS mediates resistance to PARPi and sensitivity to PARPi and MEKi Mutant KRAS mediates resistance to PARPi and sensitivity to PARPi and.
Supplemental figure 1B Indicated cell lines were incubated with venetoclax (VEN) in combination with ara-C or idarubicin (IDA), for 48h and viability assessed.

Supplemental figure 1B Indicated cell lines were incubated with venetoclax (VEN) in combination with ara-C or idarubicin (IDA), for 48h and viability assessed.
Drug network derived from the core EGFR interactome and combination strategy to overcome the resistant cells. Drug network derived from the core EGFR interactome.

Drug network derived from the core EGFR interactome and combination strategy to overcome the resistant cells. Drug network derived from the core EGFR interactome.
Level of EGFR inhibition determines cell death response in EGFR mutant GBM cells. Level of EGFR inhibition determines cell death response in EGFR mutant.

Level of EGFR inhibition determines cell death response in EGFR mutant GBM cells. Level of EGFR inhibition determines cell death response in EGFR mutant.
Kavitha Gowrishankar, Stephanie Snoyman, Gulietta M. Pupo, Therese M

Kavitha Gowrishankar, Stephanie Snoyman, Gulietta M. Pupo, Therese M
Figure 1. A CRISPR/Cas9 synthetic lethal screen with PRMT5 inhibitor EPZ015666 in H2171 cell line. (A) A pie chart ... Figure 1. A CRISPR/Cas9 synthetic.

Figure 1. A CRISPR/Cas9 synthetic lethal screen with PRMT5 inhibitor EPZ in H2171 cell line. (A) A pie chart ... Figure 1. A CRISPR/Cas9 synthetic.

Similar presentations

Ads by Google